Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person crizotinib-resistant ALK mutants don't bind crizotinib

Class:IdFailedReaction:9715357
_displayNamecrizotinib-resistant ALK mutants don't bind crizotinib
_doReleaseTRUE
_timestamp2021-05-12 13:25:41
authored[InstanceEdit:9724129] Rothfels, Karen, 2021-03-22
compartment[Compartment:70101] cytosol
[Compartment:876] plasma membrane
created[InstanceEdit:9715358] Rothfels, Karen, 2021-02-17
disease[Disease:1500689] cancer
edited[InstanceEdit:9725664] Rothfels, Karen, 2021-03-30
entityFunctionalStatus[EntityFunctionalStatus:9714051] loss_of_function of crizotinib resistant ALK mutants [plasma membrane]
input[DefinedSet:9700564] crizotinib resistant ALK mutants [plasma membrane] [Homo sapiens]
[ChemicalDrug:9699597] crizotinib [cytosol]
isChimericFALSE
literatureReference[LiteratureReference:9700343] Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
[LiteratureReference:9700339] Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
[LiteratureReference:9701779] A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
[LiteratureReference:9701740] Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
[LiteratureReference:9701750] Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
[LiteratureReference:9701767] EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
[LiteratureReference:9701773] ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
[LiteratureReference:9710814] The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
[LiteratureReference:9713917] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
[LiteratureReference:9713864] ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
[LiteratureReference:9713955] Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient
[LiteratureReference:9713948] Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment
[LiteratureReference:9713890] Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing
[LiteratureReference:9713909] Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer
[LiteratureReference:9713940] Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review
[LiteratureReference:9700350] The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
[LiteratureReference:9713997] Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib
[LiteratureReference:9702293] Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib
[LiteratureReference:9713872] ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report
modified[InstanceEdit:9724130] Rothfels, Karen, 2021-03-22
[InstanceEdit:9729590] Rothfels, Karen, 2021-04-30
[InstanceEdit:9729893] Rothfels, Karen, 2021-05-04
[InstanceEdit:9730943] Rothfels, Karen, 2021-05-12
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
namecrizotinib-resistant ALK mutants don't bind crizotinib
normalReaction
releaseDate2021-06-09
reviewed[InstanceEdit:9729891] Inghirami, Giorgio, 2021-05-04
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9715359] R-HSA-9715357.2
summation[Summation:9714030] The following ALK mutants show resistance to inhibition by c...
(hasEvent)[Pathway:9717326] crizotinib-resistant ALK mutants [Homo sapiens]
(updatedInstance)[_UpdateTracker:9835720] Update Tracker - [FailedReaction:9715357] crizotinib-resistant ALK mutants don't bind crizotinib - v85:[modifyText]
[Change default viewing format]
No pathways have been reviewed or authored by crizotinib-resistant ALK mutants don't bind crizotinib (9715357)
Follow Reactome